Squarepoint Ops LLC Decreases Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Squarepoint Ops LLC cut its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 34.2% during the fourth quarter, HoldingsChannel.com reports. The fund owned 48,374 shares of the company’s stock after selling 25,151 shares during the period. Squarepoint Ops LLC’s holdings in Kymera Therapeutics were worth $1,946,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in KYMR. Blue Trust Inc. increased its position in shares of Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after purchasing an additional 270 shares during the last quarter. Summit Investment Advisors Inc. grew its position in Kymera Therapeutics by 9.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock worth $198,000 after purchasing an additional 406 shares during the last quarter. Harbor Capital Advisors Inc. increased its position in Kymera Therapeutics by 1.7% in the 4th quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company’s stock valued at $1,649,000 after acquiring an additional 684 shares during the period. KBC Group NV raised its stake in Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after acquiring an additional 752 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Kymera Therapeutics by 8.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock valued at $534,000 after purchasing an additional 915 shares during the period.

Insider Transactions at Kymera Therapeutics

In related news, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares of the company’s stock, valued at approximately $6,147,428.70. This trade represents a 3.37 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ellen Chiniara sold 2,241 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the sale, the insider now owns 80,085 shares in the company, valued at $2,438,588.25. This represents a 2.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,788 shares of company stock valued at $455,202 in the last quarter. Insiders own 15.82% of the company’s stock.

Kymera Therapeutics Price Performance

Shares of KYMR opened at $33.70 on Tuesday. The business’s fifty day moving average price is $36.72 and its 200 day moving average price is $42.18. The stock has a market capitalization of $2.19 billion, a PE ratio of -14.40 and a beta of 2.22. Kymera Therapeutics, Inc. has a 12-month low of $29.07 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on KYMR shares. BMO Capital Markets began coverage on Kymera Therapeutics in a report on Friday, December 6th. They issued a “market perform” rating and a $55.00 target price for the company. BTIG Research began coverage on Kymera Therapeutics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective on the stock. Stephens reiterated an “overweight” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $38.00 to $57.00 in a report on Monday, December 2nd. Finally, Citigroup assumed coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $52.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $56.36.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.